CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2014; 35(03): 221-225
DOI: 10.4103/0971-5851.142039
ORIGINAL ARTICLE

The seroprevalence of Kaposi′s sarcoma associated herpes virus and human herpes virus-6 in pediatric patients with cancer and healthy children in a Turkish pediatric oncology center

Nurdan Tacyildiz
Department of Pediatrics Oncology, Ankara University Medical School, Ankara, Turkey
,
Handan Ugur Dincaslan
Department of Pediatrics Oncology, Ankara University Medical School, Ankara, Turkey
,
Halil Ozdemir
Department of Pediatric Infection Diseases, Ankara University Medical School, Ankara, Turkey
,
Gulsan Yavuz
Department of Pediatrics Oncology, Ankara University Medical School, Ankara, Turkey
,
Emel Unal
Department of Pediatrics Oncology, Ankara University Medical School, Ankara, Turkey
,
Aydan Ikinciogullari
Department of Pediatric Immunology, Ankara University Medical School, Ankara, Turkey
,
Figen Dogu
Department of Pediatric Immunology, Ankara University Medical School, Ankara, Turkey
,
Deniz Guloglu
Department of Pediatric Immunology, Ankara University Medical School, Ankara, Turkey
,
Emine Suskan
Department of Pediatrics, Ankara University Medical School, Ankara, Turkey
,
Kenan Kose
Department of Biostatistics, Ankara University Medical School, Ankara, Turkey
› Author Affiliations

Abstract

Background: Many studies have tried to be establish a pathogenic role for human herpesvirus-6 and -8 (HHV-6, HHV-8) in malignant diseases, but whether these viruses plays a role in these pathologies remains unclear. HHV-6 and HHV-8 seropositivity were shown in a healthy population. There is no published data in Turkey about seroprevalence of these viruses. We aimed to determine the seroprevalence of HHV-6 and HHV-8 in pediatric cancer patients and to compare with healthy Turkish children′s viral seroprevalence. Patients and Methods: Ninety-three pediatric cancer patients and 43 age-matched healthy children were included in the study. All sera were screened for antibodies to HHV-6 and HHV-8 by ELISA. Results: HHV-8 immunoglobulin G (IgG) was positive in 3.3% of lymphoma patients, in 4.8% of acute lymphoblastic leukemia (ALL) patients, in 4.8% of retinoblastoma patients and in 7% of healthy children. There was no significant difference in HHV-8 seroprevelance between these groups. HHV-6 seroprevalence was 81% in ALL patients, 70% in lymphoma group, 81% in retinoblastoma patients and 69.8% in healthy children. Although there was no significant difference in HHV-6 prevalence between healthy children and pediatric cancer patients, HHV-6 seropositivity tended to be higher in retinoblastoma patients under age of 4 years (odds ratio: 2.925). Conclusion: HHV-6 seroprevalence was higher than HHV-8 seropositivity in our study. Viral studies related HHV-6 seroprevelance in retinoblastoma patients would be useful to clarify if there is any etiological association between HHV-6 and retinoblastoma.



Publication History

Article published online:
19 July 2021

© 2014. Indian Society of Medical and Paediatric Oncology. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/.)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 
  • References

  • 1 Chang Y, Cesarman E, Pessin MS, Lee F, Culpepper J, Knowles DM, et al. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi′s sarcoma. Science 1994;266:1865-9.
  • 2 Cesarman E, Chang Y, Moore PS, Said JW, Knowles DM. Kaposi′s sarcoma-associated herpesvirus-like DNA sequences in AIDS-related body-cavity-based lymphomas. N Engl J Med 1995;332:1186-91.
  • 3 Soulier J, Grollet L, Oksenhendler E, Cacoub P, Cazals-Hatem D, Babinet P, et al. Kaposi′s sarcoma-associated herpesvirus-like DNA sequences in multicentric Castleman′s disease. Blood 1995;86:1276-80.
  • 4 Dupin N, Diss TL, Kellam P, Tulliez M, Du MQ, Sicard D, et al. HHV-8 is associated with a plasmablastic variant of Castleman disease that is linked to HHV-8-positive plasmablastic lymphoma. Blood 2000;95:1406-12.
  • 5 Du MQ, Diss TC, Liu H, Ye H, Hamoudi RA, Cabeçadas J, et al. KSHV- and EBV-associated germinotropic lymphoproliferative disorder. Blood 2002;100:3415-8.
  • 6 Ferry JA, Sohani AR, Longtine JA, Schwartz RA, Harris NL. HHV8-positive, EBV-positive Hodgkin lymphoma-like large B-cell lymphoma and HHV8-positive intravascular large B-cell lymphoma. Mod Pathol 2009;22:618-26.
  • 7 Lennette ET, Blackbourn DJ, Levy JA. Antibodies to human herpesvirus type 8 in the general population and in Kaposi′s sarcoma patients. Lancet 1996;348:858-61.
  • 8 Salahuddin SZ, Ablashi DV, Markham PD, Josephs SF, Sturzenegger S, Kaplan M, et al. Isolation of a new virus, HBLV, in patients with lymphoproliferative disorders. Science 1986;234:596-601.
  • 9 Kondo K, Kondo T, Shimada K, Amo K, Miyagawa H, Yamanishi K. Strong interaction between human herpesvirus 6 and peripheral blood monocytes/macrophages during acute infection. J Med Virol 2002;67:364-9.
  • 10 Kondo K, Kondo T, Okuno T, Takahashi M, Yamanishi K. Latent human herpesvirus 6 infection of human monocytes/macrophages. J Gen Virol 1991;72:1401-8.
  • 11 Ogata M. Human herpesvirus 6 in hematological malignancies. J Clin Exp Hematop 2009;49:57-67.
  • 12 Torelli G, Marasca R, Luppi M, Selleri L, Ferrari S, Narni F, et al. Human herpesvirus-6 in human lymphomas: identification of specific sequences in Hodgkin′s lymphomas by polymerase chain reaction. Blood 1991;77:2251-8.
  • 13 Sumiyoshi Y, Kikuchi M, Ohshima K, Takeshita M, Eizuru Y, Minamishima Y. Analysis of human herpes virus-6 genomes in lymphoid malignancy in Japan. J Clin Pathol 1993;46:1137-8.
  • 14 Lacroix A, Jaccard A, Rouzioux C, Piguet C, Petit B, Bordessoule D, et al. HHV-6 and EBV DNA quantitation in lymph nodes of 86 patients with Hodgkin′s lymphoma. J Med Virol 2007;79:1349-56.
  • 15 Trovato R, Di Lollo S, Calzolari A, Torelli G, Ceccherini-Nelli L. Detection of human herpesvirus-6 and Epstein-Barr virus genome in childhood Hodgkin′s disease. Pathologica 1994;86:500-3.
  • 16 Valente G, Secchiero P, Lusso P, Abete MC, Jemma C, Reato G, et al. Human herpesvirus 6 and Epstein-Barr virus in Hodgkin′s disease: a controlled study by polymerase chain reaction and in situ hybridization. Am J Pathol 1996;149:1501-10.
  • 17 Luppi M, Barozzi P, Garber R, Maiorana A, Bonacorsi G, Artusi T, et al. Expression of human herpesvirus-6 antigens in benign and malignant lymphoproliferative diseases. Am J Pathol 1998;153:815-23.
  • 18 Schmidt CA, Oettle H, Peng R, Binder T, Wilborn F, Huhn D, et al. Presence of human beta- and gamma-herpes virus DNA in Hodgkin′s disease. Leuk Res 2000;24:865-70.
  • 19 Salonen MJ, Siimes MA, Salonen EM, Vaheri A, Koskiniemi M. Antibody status to HHV-6 in children with leukaemia. Leukemia 2002;16:716-9.
  • 20 Yoshikawa T, Suga S, Asano Y, Yazaki T, Kodama H, Ozaki T. Distribution of antibodies to a causative agent of exanthem subitum (human herpesvirus-6) in healthy individuals. Pediatrics 1989;84:675-7.
  • 21 Zerr DM, Meier AS, Selke SS, Frenkel LM, Huang ML, Wald A, et al. A population-based study of primary human herpesvirus 6 infection. N Engl J Med 2005;352:768-76.
  • 22 Liang C, Lee JS, Jung JU. Immune evasion in Kaposi′s sarcoma-associated herpes virus associated oncogenesis. Semin Cancer Biol 2008;18:423-36.
  • 23 Wen KW, Damania B. Kaposi sarcoma-associated herpesvirus (KSHV): molecular biology and oncogenesis. Cancer Lett 2010;289:140-50.
  • 24 Sunil M, Reid E, Lechowicz MJ. Update on HHV-8-Associated Malignancies. Curr Infect Dis Rep 2010;12:147-54.
  • 25 Cathomas G. Kaposi′s sarcoma-associated herpesvirus (KSHV)/human herpesvirus 8 (HHV-8) as a tumour virus. Herpes 2003;10:72-7.
  • 26 Radkov SA, Kellam P, Boshoff C. The latent nuclear antigen of Kaposi sarcoma-associated herpesvirus targets the retinoblastoma-E2F pathway and with the oncogene Hras transforms primary rat cells. Nat Med 2000;6:1121-7.
  • 27 Sullivan RJ, Pantanowitz L, Casper C, Stebbing J, Dezube BJ. HIV/AIDS: epidemiology, pathophysiology, and treatment of Kaposi sarcoma-associated herpesvirus disease: Kaposi sarcoma, primary effusion lymphoma, and multicentric Castleman disease. Clin Infect Dis 2008;47:1209-15.
  • 28 Cattani P, Cerimele F, Porta D, Graffeo R, Ranno S, Marchetti S, et al. Age-specific seroprevalence of Human Herpesvirus 8 in Mediterranean regions. Clin Microbiol Infect 2003;9:274-9.
  • 29 Zerr DM. Human herpesvirus 6: a clinical update. Herpes 2006;13:20-4.
  • 30 Levine PH, Ablashi DV, Saxinger WC, Connelly RR. Antibodies to human herpes virus-6 in patients with acute lymphocytic leukemia. Leukemia 1992;6:1229-31.
  • 31 Luka J, Pirruccello SJ, Kersey JH. HHV-6 genome in T-cell acute lymphoblastic leukaemia. Lancet 1991;338:1277-8.
  • 32 Barozzi P, Luppi M, Marasca R, Trovato R, Ceccherini-Nelli L, Torelli G. Human herpesvirus-6 genome in acute lymphoblastic leukemia: evidence against an etiologic relationship. Acta Haematol 1995;94:169-72.
  • 33 Seror E, Coquerel B, Gautheret-Dejean A, Ballerini P, Landman-Parker J, Leverger G, et al. Quantitation of Human herpes virus 6 genome in children with acute lymphoblastic leukemia. J Med Virol 2008;80:689-93.
  • 34 Mlechkovich G, Frenkel N. Human herpesvirus 6A (HHV-6A) and HHV-6B alter E2F1/Rb pathways and E2F1 localization and cause cell cycle arrest in infected T cells. J Virol 2007;81:13499-508.